← Eichor
Condition: Dravet Syndrome Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Dravet Syndrome

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Evaluate the Safety and Pharmacokinetics of RC001 in Children With Dravet Syndrome
EARLY_Phase 1 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT07675746A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
Phase 3 · 58 location(s) · Stoke Therapeutics, Inc · NCT06872125Registry and Natural History of Epilepsy-Dyskinesia Syndromes
Phase N/A · 1 location(s) · Boston Children's Hospital · NCT06967727ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
Phase 1/Phase 2 · 3 location(s) · Ionis Pharmaceuticals, Inc. · NCT07531745International CDKL5 Clinical Research Network
Phase N/A · 9 location(s) · University of Colorado, Denver · NCT05558371Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age
Phase 4 · 1 location(s) · University of Colorado, Denver · NCT06598449SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom
Phase N/A · 1 location(s) · NHS Greater Glasgow and Clyde · NCT06504511A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia
Phase N/A · 1 location(s) · Boston Children's Hospital · NCT06585605A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndro
Phase 1/Phase 2 · 14 location(s) · Encoded Therapeutics · NCT05419492A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
Phase 3 · 102 location(s) · Longboard Pharmaceuticals · NCT06660394Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT07251673A PET-MRI Study of Serotoninergic Brainstem Pathway in Patients With Dravet Syndrome
NA · 1 location(s) · Hospices Civils de Lyon · NCT07013331A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
Phase 3 · 60 location(s) · Epygenix · NCT04462770BMB-101 in Absence Epilepsy and DEE
Phase 2 · 5 location(s) · Bright Minds Biosciences Pty Ltd · NCT06401538The FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome Project
Phase 4 · 1 location(s) · The University of Texas Health Science Center, Houston · NCT07112365Multicentre Real-life Follow-up Study of Rare Epileptic Syndromes in Children and Adolescents
Phase N/A · 11 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05126914GABA Biomarkers in Dravet Syndrome
Phase N/A · 1 location(s) · Cook Children's Health Care System · NCT05651204
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.